Please try another search
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics by its i-body platform in Australia. Its lead product is AD-214, an antibody therapeutic, which is in Phase I clinical trial for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis and interstitial lung disease, kidney fibrosis, eye fibrosis, and various cancers. AdAlta Limited has collaborative partnerships with GE Healthcare to develop i-body enabled granzyme B PET imaging agents for use in immuno-oncology; and Carina Biotech to develop CAR-T cell products against various solid tumor antigens. The company was incorporated in 2006 and is based in Bundoora, Australia.
Name | Age | Since | Title |
---|---|---|---|
Timothy Charles Oldham | - | 2019 | CEO, MD & Director |
Paul Donald Richard MacLeman | 55 | 2015 | Non-Executive Chairman |
David Everett Fuller | 59 | 2020 | Non-Executive Director |
Robert Peach | 67 | 2016 | Independent Non-Executive Director |
Brian Richardson | - | - | Scientific Advisor |
John Westwick | - | - | Scientific Advisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review